Keeping patients out of care facilities--- clozapine rescues Parkinson's patients with troublesome psychosis unresponsive to quetiapine and pimavanserin

被引：0
|
作者：
Iseringhausen, J.
Riboldi, G.
Astudillo, K.
Frucht, S.
机构：
来源：
MOVEMENT DISORDERS | 2023年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
1909
引用
收藏
页码：S837 / S837
页数：1
相关论文
共 50 条
  • [21] An open-label extension study to determine the safety of pimavanserin in patients with Parkinson's disease and psychosis
    Mills, R.
    Johnson, A. D.
    Bahr, D.
    Williams, H.
    Revell, S.
    MOVEMENT DISORDERS, 2009, 24 : S268 - S269
  • [22] Motor-Related and Cognition-Related Safety of Pimavanserin in Patients with Parkinson's Disease Psychosis
    Espay, A.
    Abler, V.
    Ballard, C.
    Berrio, A.
    Coate, B.
    Brain, C.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2020, 70 : S191 - S192
  • [23] The experience of care partners of patients with Parkinson's disease psychosis
    Mantri, Sneha
    Klawson, Emily
    Albert, Steven
    Rapoport, Robyn
    Precht, Chelle
    Glancey, Sarah
    Daeschler, Margaret
    Mamikonyan, Eugenia
    Kopil, Catherine M.
    Marras, Connie
    Chahine, Lana M.
    PLOS ONE, 2021, 16 (03):
  • [24] Risk of mortality associated with pimavanserin compared with atypical antipsychotics in patients with Parkinson's disease-Related psychosis
    Layton, J. Bradley
    McQuay, Lisa
    Forns, Joan
    Danysh, Heather
    Dempsey, Colleen
    Anthony, Mary
    Turner, Mary Ellen
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 57 - 58
  • [25] Quetiapine in the treatment of psychosis in patients with Parkinson's disease and dementia (Lewy body disease variant)
    Parsa, M
    Greenaway, H
    Bastiani, B
    ANNALS OF NEUROLOGY, 2001, 50 (03) : S77 - S77
  • [26] Motor-related and cognition-related safety of pimavanserin in patients with Parkinson's disease psychosis (PDP)
    Abler, V.
    Ballard, C.
    Berrio, A.
    Coate, B.
    Brain, C.
    Espay, A.
    MOVEMENT DISORDERS, 2022, 37 : S365 - S365
  • [27] Risk of Long-term Care Admissions Among Medicare Patients Treated with Pimavanserin or Other Atypical Antipsychotics for Parkinson's Disease Psychosis
    Kumar, S.
    Rashid, N.
    Doshi, D.
    Rajagopalan, K.
    MOVEMENT DISORDERS, 2022, 37 : S369 - S369
  • [28] Health care resource utilization patterns among patients with Parkinson's disease psychosis: analysis of Medicare beneficiaries treated with pimavanserin or other-atypical antipsychotics
    Rajagopalan, Krithika
    Rashid, Nazia
    Kumar, Shikhar
    Doshi, Dilesh
    JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 34 - 42
  • [29] Falls and Fractures in Patients with Parkinson's Disease-Related Psychosis Treated with Pimavanserin vs Atypical Antipsychotics: A Cohort Study
    Layton, J. Bradley
    Forns, Joan
    Turner, Mary Ellen
    Dempsey, Colleen
    Bartsch, Jennifer L.
    Anthony, Mary S.
    Danysh, Heather E.
    Ritchey, Mary E.
    Demos, George
    DRUGS-REAL WORLD OUTCOMES, 2022, 9 (01) : 9 - 22
  • [30] Mortality in Patients with Parkinson's Disease-Related Psychosis Treated with Pimavanserin Compared with Other Atypical Antipsychotics: A Cohort Study
    Layton, J. Bradley
    Forns, Joan
    McQuay, Lisa J.
    Danysh, Heather E.
    Dempsey, Colleen
    Anthony, Mary S.
    Turner, Mary Ellen
    DRUG SAFETY, 2023, 46 (02) : 195 - 208
12345